CHM and choroideremia: Gene therapy in choroideremia requires areas of relatively preserved retinal architecture, such that AAV2-REP1 can transduce in surviving RPE and photoreceptor cells, resulting in the production of functioning REP1 and consequent prenylation activity [68].